| 1. |
- Wit, J M., et al.
(författare)
-
Personalized Approach to Growth Hormone Treatment: Clinical Use of Growth Prediction Models
- 2013
-
Ingår i: Hormone Research in Paediatrics. - : Karger. - 1663-2818 .- 1663-2826. ; 79:5, s. 257-270
-
Forskningsöversikt (refereegranskat)abstract
- The goal of growth hormone (GH) treatment in a short child is to attain a fast catch-up growth toward the target height (TH) standard deviation score (SDS), followed by a maintenance phase, a proper pubertal height gain, and an adult height close to TH. The short-term response variable of GH treatment, first-year height velocity (HV) (cm/year or change in height SDS), can either be compared with GH response charts for diagnosis, age and gender, or with predicted HV based on prediction models. Three types of prediction models have been described: the Kabi International Growth Hormone Study models, the Gothenburg models and the Cologne model. With these models, 50-80% of the variance could be explained. When used prospectively, individualized dosing reduces the variation in growth response in comparison with a fixed dose per body weight. Insulin-like growth factor-I-based dose titration also led to a decrease in the variation. It is uncertain whether adding biochemical, genetic or proteomic markers may improve the accuracy of the prediction. Prediction models may lead to a more evidence-based approach to determine the GH dose regimen and may reduce the drug costs for GH treatment. There is a need for user-friendly software programs to make prediction models easily available in the clinic.
|
|
| 2. |
- Jansson, Stefan, 1959-, et al.
(författare)
-
Antenna protein composition of PS I and PS II in thylakoid sub-domains
- 1997
-
Ingår i: Biochimica et Biophysica Acta - Bioenergetics. - 0005-2728 .- 1879-2650. ; 1320:3, s. 297-309
-
Tidskriftsartikel (refereegranskat)abstract
- Spinach thylakoids were separated into grana core, grana margin, and two different stromal lamella fractions in the absence of detergents. The levels of all light-harvesting chlorophyll a/b-binding (LHC) proteins were determined in all fractions, and were normalised to the amount of Photosystem I (PS I) and Photosystem II (PS II) centres. PS I beta in the stroma lamellae was found to have a full complement of Lhca polypeptides and, probably, one attached LHC II trimer. PS I alpha binds additional LHC II trimers, but PS I centres located in the inner parts of the grana stack lack Lhca1 and are depleted in Lhca4. PS II beta, found in grana margins and stroma lamellae, seems to associate one monomer each of Lhcb4, Lhcb5 and Lhcb6 (CP29, CP76 and CP24, respectively) and one LHC II trimer consisting of two Lhcb1 and one Lhcb3 subunit. PS II alpha has additional LHC II trimers (consisting of Lhcb1 and Lhcb2) attached. We also find evidence for the existence of both PS I and PS II centres in the extreme stroma (probably centres being synthesised or repaired), that lack all LHC proteins. (C) 1997 Published by Elsevier Science B.V.
|
|
| 3. |
- Schrier, Lenneke, et al.
(författare)
-
Comparison of Body Surface Area versus Weight-Based Growth Hormone Dosing for Girls with Turner Syndrome
- 2014
-
Ingår i: Hormone Research in Paediatrics. - : S. Karger AG. - 1663-2818 .- 1663-2826. ; 81:5, s. 319-330
-
Tidskriftsartikel (refereegranskat)abstract
- Background/Aims: Growth Hormone (GH) dosage in childhood is adjusted for body size, but there is no consensus whether body weight (BW) or body surface area (BSA) should be used. We aimed at comparing the biological effect and cost-effectiveness of GH treatment dosed per m(2) BSA in comparison with dosing per kg BW in girls with Turner syndrome (TS). Methods: Serum IGF-I, GH dose, and adult height gain (AHG) from girls participating in two Dutch and five Swedish studies on the efficacy of GH were analyzed, and the cumulative GH dose and costs were calculated for both dose adjustment methods. Additional medication included estrogens (if no spontaneous puberty occurred) and oxandrolone in some studies. Results: At each GH dose, the serum IGF-I standard deviation score remained stable over time after an initial increase after the start of treatment. On a high dose (at 1 m(2) equivalent to 0.056-0.067 mg/kg/day), AHG was at least equal on GH dosed per m(2) BSA compared with dosing per kg BW. The cumulative dose and cost were significantly lower if the GH dose was adjusted for m(2) BSA. Conclusion: Dosing GH per m(2) BSA is at least as efficacious as dosing per kg BW, and is more cost-effective. (C) 2014 S. Karger AG, Basel
|
|
